Fresh analysis reveals that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who end conventional lifestyle regimens.
Published data in a leading health publication points out that while overweight people frequently drop substantial amounts of their body weight while on the medication, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"People using such treatments must be informed of the potential of fast weight regain when the medication ends," stated lead investigator Dr. Susan Jebb.
Such speed of recovery implies a return to pre-treatment weight in about 18 months.
Weighing Treatments
The research, which looked at dozens of studies involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.
Scientists note that people who shed pounds through diet and exercise usually experience a slower creep back—approximately 0.1 kg a month—post-intervention.
The Reason for the Fast Regain
Experts believe the mode of action of the injections accounts for the heightened rebound.
The injections copy a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone levels several times higher than normal may cause the system to produce less of its endogenous hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication leads to hunger is unsuppressed, making binge eating much more probable."
A Lifelong Issue?
Medical guidelines advise the jabs for people with weight-linked medical conditions, alongside prescribed lifestyle changes.
Professionals argue that, considering the likelihood of relapse, the therapy might need to be long-term.
This view is reinforced by pharmaceutical companies, who say that the findings "underscore the long-term character of excess weight," akin to managing diseases like diabetes.
Patient Experiences
Individuals who have come off the jabs report a intense resurgence of appetite.
"It was like something that goes on and you become extremely hungry," described an individual.
This difficulty is exacerbated if users have not adopted lasting dietary or behavioural changes during therapy.
Growing Adoption
Figures show that millions of adults in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Adoption is more common among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, clinicians stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic fix and long-term success relies on combined lifestyle management.
